Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives
- 31 January 2011
- journal article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 46 (1), 327-340
- https://doi.org/10.1016/j.ejmech.2010.11.022
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanomaEuropean Journal of Pharmaceutical Sciences, 2010
- Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cellsEuropean Journal of Pharmacology, 2009
- A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursEuropean Journal of Cancer, 2008
- Part 3: Synthesis and biological evaluation of some analogs of the antitumor agents, 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid, and 2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acidBioorganic & Medicinal Chemistry, 2005
- Targeting c-Kit mutations: basic science to novel therapiesLeukemia Research, 2004
- Protein Kinase Inhibitors as a Therapeutic ModalityAccounts of Chemical Research, 2003
- II. Synthesis and Biological Evaluation of Some Bioisosteres and Congeners of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)Journal of Medicinal Chemistry, 2002
- Recent Progress in the Development of Anticancer AgentsCurrent Medicinal Chemistry - Anti-Cancer Agents, 2002
- Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)Journal of Medicinal Chemistry, 2001
- Kinetics of phosphorylation of the SH2-containing domain of phospholipase Cγ1 by the epidermal growth factor receptorFEBS Letters, 1994